9-Jan-2026
TipRanks (Thu, 8-Jan 10:26 AM ET)
Vanda falls as FDA rejects jet lag drug
Seeking Alpha News (Thu, 8-Jan 7:47 AM ET)
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application
TipRanks (Thu, 8-Jan 7:29 AM ET)
PRNewswire (Thu, 8-Jan 7:00 AM ET)
PRNewswire (Tue, 30-Dec 6:13 PM ET)
Market Chameleon (Mon, 15-Dec 3:37 AM ET)
PRNewswire (Mon, 15-Dec 7:00 AM ET)
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
PRNewswire (Thu, 11-Dec 5:02 PM ET)
FDA Clears Path for Vanda’s Tradipitant: Clinical Hold Lifted and PDUFA Decision Looms
Market Chameleon (Fri, 5-Dec 6:10 AM ET)
Market Chameleon (Fri, 5-Dec 3:39 AM ET)
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Vanda Pharmaceuticals trades on the NASDAQ stock market under the symbol VNDA.
As of January 9, 2026, VNDA stock price declined to $7.33 with 1,219,872 million shares trading.
VNDA has a beta of 0.49, meaning it tends to be less sensitive to market movements. VNDA has a correlation of 0.03 to the broad based SPY ETF.
VNDA has a market cap of $433.18 million. This is considered a Small Cap stock.
Last quarter Vanda Pharmaceuticals reported $56 million in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.02.
In the last 3 years, VNDA traded as high as $9.60 and as low as $3.30.
The top ETF exchange traded funds that VNDA belongs to (by Net Assets): IWM, VTI, IWN, IBB, VXF.
VNDA has outperformed the market in the last year with a price return of +57.6% while the SPY ETF gained +19.0%. VNDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +34.5% and +4.1%, respectively, while the SPY returned +3.7% and +0.5%, respectively.
VNDA support price is $7.00 and resistance is $7.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNDA shares will trade within this expected range on the day.